Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin B Kim

Showing results (91-100 of 134) with videos related to

Pageof 14
Sort By:
Cancer Research|March 26, 2021
Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation-Induced DNA Damage and Melanoma SusceptibilityDavid de Semir, Vladimir Bezrookove, Mehdi Nosrati, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
JAMA Network Open|April 19, 2023
Improving Selection for Sentinel Lymph Node Biopsy Among Patients With MelanomaJames R Miller, Serigne N Lo, Mehdi Nosrati, et al.
Molecular Cancer Therapeutics|August 13, 2009
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlatesScott E Woodman, Jonathan C Trent, Katherine Stemke-Hale, et al.
Immunity|November 1, 2025
Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitorsMingming Wu, Shiyue Yang, Zhentao Yang, et al.
Cancer|March 26, 2004
Biochemotherapy in patients with metastatic anorectal mucosal melanomaKevin B Kim, Angela M Sanguino, Cynthia Hodges, et al.
Melanoma Research|June 7, 2012
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanomaKevin B Kim, Victor Prieto, Richard W Joseph, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapyYong Qin, Kathryn Bollin, Mariana Petaccia de Macedo, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2022
Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanomaAltaf A Dar, Vladimir Bezrookove, Mehdi Nosrati, et al.
Lancet (London, England)|May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Pageof 14

Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
Cancer Research|March 26, 2021
Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation-Induced DNA Damage and Melanoma SusceptibilityDavid de Semir, Vladimir Bezrookove, Mehdi Nosrati, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
JAMA Network Open|April 19, 2023
Improving Selection for Sentinel Lymph Node Biopsy Among Patients With MelanomaJames R Miller, Serigne N Lo, Mehdi Nosrati, et al.
Molecular Cancer Therapeutics|August 13, 2009
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlatesScott E Woodman, Jonathan C Trent, Katherine Stemke-Hale, et al.
Immunity|November 1, 2025
Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitorsMingming Wu, Shiyue Yang, Zhentao Yang, et al.
Cancer|March 26, 2004
Biochemotherapy in patients with metastatic anorectal mucosal melanomaKevin B Kim, Angela M Sanguino, Cynthia Hodges, et al.
Melanoma Research|June 7, 2012
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanomaKevin B Kim, Victor Prieto, Richard W Joseph, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapyYong Qin, Kathryn Bollin, Mariana Petaccia de Macedo, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2022
Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanomaAltaf A Dar, Vladimir Bezrookove, Mehdi Nosrati, et al.
Lancet (London, England)|May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Pageof 14